Full coverage· Health· Updated
New Weekly Insulin Awiqli Launches in Israel for Diabetes Patients
A new once-weekly insulin, Awiqli, has been approved and is now available in Israel for diabetes patients, significantly reducing the number of annual injections. Developed by Novo Nordisk, the drug offers convenience and improved blood sugar control, according to patient and physician accounts.
2 newsrooms · 2 languages · since
Plus
What happened
- 01Awiqli, the first once-weekly insulin, is now available in Israel for diabetes patients.
- 02The new drug reduces annual injections from 365 to just 52.
- 03Awiqli is currently available privately, with prices ranging from 280 to 527 shekels.
- 04Over 700,000 people in Israel live with diabetes, with type 2 being the most common.
- 05Clinical trials showed Awiqli to be as effective as, and in some cases more effective than, daily basal insulin.
While currently available privately, its introduction is seen as a major advancement in diabetes therapy, potentially easing treatment for many. The drug has already received approvals in the EU and the U.S.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- CentreNone
- RightNone
- HarediNone
- Arab1
- Other1
How it broke
See which of the 2 newsrooms broke it, and who waited